Les agonistes α2-adrénergiques pour l’intensiviste [Alpha-2 adrenoreceptor agonists for the intensive care physician]
Fiche du document
3 mai 2023
- doi: 10.53738/REVMED.2023.19.825.872
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2023.19.825.872
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/37139883
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_CDD4BF43C3E14
info:eu-repo/semantics/embargoedAccess , Restricted: cannot be viewed until 2024-11-03 , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Circumcellians AgonistsCiter ce document
L. Gavino et al., « Les agonistes α2-adrénergiques pour l’intensiviste [Alpha-2 adrenoreceptor agonists for the intensive care physician] », Serveur académique Lausannois, ID : 10.53738/REVMED.2023.19.825.872
Métriques
Partage / Export
Résumé
Clonidine and dexmedetomidine are two α2-adrenoreceptors agonists available for the intensivist in the clinical practice. The affinity of dexmedetomidine is eight times greater than clonidine affinity for the α2 receptors. Their main effect is sedation. They act by inhibition of noradrenaline release in the locus coeruleus in the brainstem. α2-agonists are used primarily for sedation, analgesia, and management of delirium. Nowadays, dexmedetomidine application is increasing in critically ill patients showing a good safety. Most frequent side effects include bradycardia and hypotension.